TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline

TherapeuticsMD (NASDAQ: TXMD) reported second-quarter 2026 license revenue of $864,000, down approximately 9.2% from $952,000 a year earlier, while net income from continuing operations fell approximately 69.9% to $164,000 from $545,000. Operating expenses increased modestly, and the company ended the June 30 quarter with $9.2 million in cash and cash equivalents.

Core Financial Results

The quarter combined lower license revenue with a small increase in operating expenses. TherapeuticsMD attributed the revenue decline to changes in sales of licensed products, while the release did not identify a specific reason for the higher expense base.

Net income remained positive but declined substantially year over year. Because the company reported only selected financial figures, the release does not provide enough detail to reconcile net income with license revenue and operating expenses fully.

The release described the license revenue decline as $83,000, although the displayed quarterly figures differ by $88,000. The percentage above is calculated from the reported current- and prior-year amounts.

Royalty Business Performance

License revenue was generated primarily through the Mayne License Agreement. The company did not provide a product-by-product breakdown, but it said the overall decrease reflected changes in sales of licensed products.

TherapeuticsMD has operated as a pharmaceutical royalty company since December 2022 and no longer conducts research and development or commercial operations. Its quarterly revenue therefore depends heavily on licensees’ product sales and the timing of royalty and milestone payments.

Profitability, Cash, and Balance Sheet

Operating expenses exceeded license revenue by $821,000 during the quarter, compared with a difference of $695,000 a year earlier. At the same time, net income from continuing operations was positive, indicating that license revenue and operating expenses alone do not present the full earnings picture; the selected results did not disclose the other line items needed for a complete explanation.

Cash and cash equivalents totaled $9.2 million at June 30, 2026. No comparable prior-year cash balance, operating cash flow, or free cash flow figure was provided, so the release does not establish whether liquidity improved or deteriorated during the quarter.

Lower Licensee Sales Weighed on Q2, While an IMVEXXY Milestone Will Enter Q3

After the quarter ended, Knight Therapeutics notified TherapeuticsMD that the IMVEXXY net sales milestone for the year ended December 31, 2025 had been achieved. TherapeuticsMD is entitled to CAD 500,000, or approximately US$364,800, and plans to recognize the milestone as revenue in the third quarter of 2026 under its accounting policies.

That amount is equivalent to approximately 42% of second-quarter license revenue, making its timing material relative to the company’s current revenue base. It is not part of the reported Q2 results, however, and should be distinguished from recurring license revenue tied directly to ongoing product sales.

Management Commentary

TherapeuticsMD continues to evaluate strategic alternatives, including a potential acquisition, merger, business combination, asset sale, or another strategic transaction. The company has not established a timetable and said there is no assurance that the review will result in a transaction or successful outcome.

Recent Insider Transactions

The supplied insider data reports no purchases or sales during the latest six-month period and approximately 1.05 million shares held by insiders. Among the last two years of records, the following transactions were explicitly identified as direct purchases; entries without a stated transaction direction or value are excluded.

These historical purchases do not, by themselves, establish insiders’ expectations for the company’s future performance.

Risks Investors Should Watch

• Dependence on licensee sales: Q2 license revenue declined because of changes in sales of licensed products. Further weakness in licensees’ commercialization performance could reduce royalty revenue.
• Uneven revenue timing: The IMVEXXY milestone will be recognized in Q3 rather than Q2, illustrating how milestone timing can create substantial quarter-to-quarter variation.
• Expenses relative to recurring revenue: Operating expenses of $1.685 million were nearly twice the quarter’s license revenue, increasing the importance of other income items and milestone receipts to reported profitability.
• Mayne Pharma uncertainty: Revenue came primarily from the Mayne License Agreement, while the company also identified ongoing disputes with Mayne Pharma as a risk.
• Strategic and liquidity uncertainty: The strategic review has no timetable or guaranteed outcome. The company also identified its ability to continue as a going concern and remain listed on Nasdaq among its risks.

Summary

TherapeuticsMD’s Q2 2026 results reflected lower license revenue, slightly higher operating expenses, and a substantial decline in net income from continuing operations. The upcoming IMVEXXY milestone should add revenue in Q3, but the quarter reinforced the company’s dependence on licensee sales, milestone timing, and the unresolved outcome of its strategic review.